Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CanTEN: Shortening Treatment Duration in Uncomplicated Candidemia
2026-525640-14-00Phase 4Authorised
- Sponsor
- University of Cologne
- Start
- May 2026
- Modality
- Antimicrobial Peptides → Native Peptides → Peptides, Cyclic Peptides → Modified Peptides → Peptides, Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial in candidemia and invasive candidiasis comparing Standard-duration caspofungin with Shortened-duration caspofungin with placebo (2 arms). Planned start May 2026; status: authorised.
02
Drugs
caspofungin
03
Conditions
candidemiainvasive candidiasis
Beyond the preview
Go deeper on 2026-525640-14-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2026-525640-14-00.